Reliable and scalable procedures for the isolation and loading of extracellular vesicles
Exosome-based therapies are among the hottest topics in biomedical research, driven by the unique properties of exosomes regarding stability, low immunogenicity, prolonged circulation and especially, selective targeting. In 2022,...
Exosome-based therapies are among the hottest topics in biomedical research, driven by the unique properties of exosomes regarding stability, low immunogenicity, prolonged circulation and especially, selective targeting. In 2022, over 50 clinical trials using exosomes for therapy were under way, in diseases ranging from cancer to diabetes to central nervous system disorders. However, both current research on exosomes and their future translation into clinical therapies are hindered by two significant problems. The first is the isolation of exosomes (and of extracellular vesicles in general), a highly challenging task due to: i) the high complexity of the body fluids that contain them, and ii) the delicate nature of exosomes themselves: soft entities of 50-150 nm whose membrane is responsible for key properties and must be preserved. Ultracentrifugation, the standard isolation method, has clear limitations: low yields, impurity of the products and damage to exosomal membranes due to long processing times at high g. While numerous alternatives have been commercialized (size, affinity and precipitation-based methods), these issues remain unsolved. The second problem relates to the loading of therapeutic agents (nanoparticles, drugs, siRNA, miRNA), into exosomes without damaging their membranes, another challenge without a solution today.
LABORIOUS leverages the experience gained in AdG CADENCE to propose innovative solutions. A novel tangential filtration procedure will segregate exosomes by size, removing impurities and minimizing pressure-induced membrane damage. Also, a pioneering continuous electroporation system will provide unprecedented control, allowing the load of therapeutic cargo with minimal membrane disruption. Results will be closely monitored for patenting and commercialization, in collaboration with an industrial observer.ver más
20-09-2024:
Industrias Agroalimentarias
Se ha cerrado la línea de ayuda pública: Ayudas 2024 para Inversiones en Industrias Agroalimentarias, Decreto 87/2024 Extremadura para el organismo:
20-09-2024:
INNOVA-ADELANTE
Se ha cerrado la línea de ayuda pública: Programa de apoyo a la innovación Castilla-La Mancha para el organismo:
Seleccionando "Aceptar todas las cookies" acepta el uso de cookies para ayudarnos a brindarle una mejor experiencia de usuario y para analizar el uso del sitio web. Al hacer clic en "Ajustar tus preferencias" puede elegir qué cookies permitir. Solo las cookies esenciales son necesarias para el correcto funcionamiento de nuestro sitio web y no se pueden rechazar.
Cookie settings
Nuestro sitio web almacena cuatro tipos de cookies. En cualquier momento puede elegir qué cookies acepta y cuáles rechaza. Puede obtener más información sobre qué son las cookies y qué tipos de cookies almacenamos en nuestra Política de cookies.
Son necesarias por razones técnicas. Sin ellas, este sitio web podría no funcionar correctamente.
Son necesarias para una funcionalidad específica en el sitio web. Sin ellos, algunas características pueden estar deshabilitadas.
Nos permite analizar el uso del sitio web y mejorar la experiencia del visitante.
Nos permite personalizar su experiencia y enviarle contenido y ofertas relevantes, en este sitio web y en otros sitios web.